+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P12603(KMT2B Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The KMT2B antibody is a crucial tool in epigenetic research, targeting the lysine-specific methyltransferase 2B (KMT2B), a histone H3 lysine 4 (H3K4) methyltransferase. KMT2B, also known as MLL4 or WBP7. is part of the KMT2 family of proteins that regulate gene expression by catalyzing mono-, di-, or trimethylation of H3K4. a key epigenetic modification associated with transcriptional activation. This enzyme plays a vital role in embryonic development, cell differentiation, and maintaining cellular identity through chromatin remodeling. Dysregulation of KMT2B has been implicated in various diseases, including neurodevelopmental disorders (e.g., childhood-onset dystonia) and cancers, where mutations or altered expression correlate with tumor progression and poor prognosis.

KMT2B antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to study its expression, localization, and functional interactions. These antibodies help identify KMT2B’s involvement in chromatin-modifying complexes, such as the COMPASS-like complex, and its role in regulating target genes. Validating antibody specificity is critical, as KMT2B shares homology with other KMT2 family members. Researchers rely on high-quality KMT2B antibodies to explore its therapeutic potential, particularly in cancers linked to epigenetic dysregulation, and to advance precision medicine approaches targeting histone-modifying enzymes.